Actively Recruiting
Screening for Dysglycemia During Postpartum Period in Women With GDM
Led by University of Sao Paulo General Hospital · Updated on 2026-05-04
182
Participants Needed
1
Research Sites
31 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Gestational diabetes mellitus (GDM) is one of the most common clinical conditions in pregnancy, with an increasing incidence due to the rise in overweight women and the postponement of motherhood. It is associated with perinatal complications and an increased risk of developing prediabetes and type 2 diabetes after delivery. Therefore, it is recommended that a 75g oral glucose tolerance test (OGTT-75g) be performed between 6 and 12 weeks postpartum. Despite its relevance, the rate of adherence to the test is low. Recent studies also indicate that measuring blood glucose one hour after the overload may be more sensitive than the traditional two-hour measurement in the early detection of dysglycemia. This study aims to evaluate strategies for qualifying the screening of metabolic changes in the postpartum period among women with GDM. The objectives are: (1) to analyze the impact of sending reminders via WhatsApp on the attendance rate for the 75g OGTT; and (2) to compare the frequency of prediabetes and diabetes diagnoses using two different diagnostic strategies applied to the same test-the traditional (fasting and 2-hour blood glucose) and the alternative (fasting and 1-hour blood glucose).
CONDITIONS
Official Title
Screening for Dysglycemia During Postpartum Period in Women With GDM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of gestational diabetes mellitus according to IADPSG criteria: fasting blood glucose 92mg/dL or 75g OGTT with fasting 92mg/dL or 1-hour 180mg/dL or 2-hour 153mg/dL
- Delivery performed at HC-FMUSP
- Scheduling of the 75g oral glucose tolerance test between 6 and 12 weeks after delivery
- Agreement with the informed consent form
You will not qualify if you...
- Withdrawal of consent
- Failure to complete the OGTT due to vomiting (exclusion from analysis 2 only)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Sao Paulo General Hospital
São Paulo, São Paulo, Brazil, 05.403-905
Actively Recruiting
Research Team
T
Tatiana A Zaccara, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SCREENING
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here